Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 28, 2018
Reporting Period: Events occurring on September 18, 2018, and September 27, 2018.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding specific corporate events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The report discloses two significant clinical and scientific developments:
- September 27, 2018: Announcement of clinical study results demonstrating similar bioavailability for a new cytisine formulation in both fed and fasted subjects.
- September 18, 2018: Announcement that the International Journal of Drug Policy published data showing superior cytisine abstinence rates compared to nicotine replacement therapy.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the reported clinical events. The report incorporates by reference press releases filed as Exhibits 99.1 and 99.2 for further details on the study results.
Investor Verification Checklist
- Verify the full text of the press releases filed as Exhibits 99.1 and 99.2 for detailed clinical data.
- Confirm the regulatory implications of the "similar bioavailability" finding for the new cytisine formulation.
- Review the specific methodology and sample size of the study published in the International Journal of Drug Policy regarding abstinence rates.